Tad H Koch

University Of Colorado At Boulder

$1,470,539

Attributed

$1,470,539

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $210.6K · FY2009–12

$250K$187.5K$125K$62.5K$0

'09

'10

'11

'12

Funding mix

By agency

NIH$1,470,539 · 4

By mechanism

R21$729,508 · 2

R01$598,415 · 1

R03$142,616 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado At Boulder

Same institution · by research overlap

Bradley B Olwin$16,268,165
Karen R Jonscher$2,269,271
David L Allen$829,468
Monika R Fleshner$6,765,440
Ruth M Barrientos$2,117,281

Others in their field

Top investigators on “Doxorubicin”

Charles A Coltman · Southwest Oncology Group$64,630,528
Norman Wolmark · Nsabp Foundation, Inc.$52,338,276
Gregory H Reaman · National Childhood Cancer Foundation$18,332,016
Laurence H Baker · University Of Michigan At Ann Arbor$12,790,926
Katherine W Ferrara · Stanford University$10,822,980
Kit S Lam · University Of California At Davis$10,711,611

Research focus

DoxorubicinFormaldehydeNeoplastic CellMass SpectrometryDisease ResistanceDrug FormulationsDrug MetabolismCardiotoxicityDesignCardiac MyocytesCell DeathCellsAbcb1 GeneCrosslinkCessation Of LifeCancer TherapyCancer EtiologyCancer CellCarboxylesteraseCarbamatesCarboxylic Ester HydrolasesBaseAdverse EffectsCleaved Cell